Accordingly, the current standard clinical practice often employs the use of recombinant granulocyte colony stimulating factors (G-CSFs) in conjunction with myelosuppressive chemotherapy with significant infection risks, to help reducing the duration of neutropenia and the risk of infection. This evidence concerns the gene CSF3 and neutropenia.